|
?:abstract
|
-
The SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) is responsible for the COVID-19 outbreak The highly contagious COVID-19 disease has spread to 216 countries in less than six months Though several vaccine candidates are being claimed, an effective vaccine is yet to come A novel reverse epitomics approach, \'overlapping-epitope-clusters-to-patches\' method is utilized to identify the antigenic regions from the SARS-CoV-2 proteome These antigenic regions are named as \'Ag-Patch or Ag-Patches\', for Antigenic Patch or Patches The identification of Ag-Patches is based on the clusters of overlapping epitopes rising from SARS-CoV-2 proteins Further, we have utilized the identified Ag-Patches to design Multi-Patch Vaccines (MPVs), proposing a novel method for the vaccine design The designed MPVs were analyzed for immunologically crucial parameters, physiochemical properties and cDNA constructs We identified 73 CTL (Cytotoxic T-Lymphocyte) and 49 HTL (Helper T-Lymphocyte) novel Ag-Patches from the proteome of SARS-CoV-2 The identified Ag-Patches utilized to design MPVs cover 768 overlapping epitopes targeting 55 different HLA alleles leading to 99 98% of world human population coverage The MPVs and Toll-Like Receptor ectodomain complex shows stable complex formation tendency Further, the cDNA analysis favors high expression of the MPVs constructs in a human cell line We identified highly immunogenic novel Ag-Patches from the entire proteome of SARS CoV-2 by a novel reverse epitomics approach and utilized them to design MPVs We conclude that the novel MPVs could be a highly potential novel approach to combat SARS-CoV-2, with greater effectiveness, high specificity and large human population coverage worldwide
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}